KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Change in Cash (2016 - 2025)

West Pharmaceutical Services' Change in Cash history spans 17 years, with the latest figure at $162.8 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 2684.13% year-over-year to $162.8 million; the TTM value through Dec 2025 reached $306.7 million, up 183.05%, while the annual FY2025 figure was $306.7 million, 183.05% up from the prior year.
  • Change in Cash for Q4 2025 was $162.8 million at West Pharmaceutical Services, up from $118.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $165.3 million in Q4 2022 and bottomed at -$252.1 million in Q1 2024.
  • The 5-year median for Change in Cash is $27.6 million (2022), against an average of $8.8 million.
  • The largest annual shift saw Change in Cash crashed 3051.25% in 2024 before it surged 2684.13% in 2025.
  • A 5-year view of Change in Cash shows it stood at $74.6 million in 2021, then surged by 121.58% to $165.3 million in 2022, then crashed by 127.04% to -$44.7 million in 2023, then surged by 85.91% to -$6.3 million in 2024, then soared by 2684.13% to $162.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Change in Cash are $162.8 million (Q4 2025), $118.8 million (Q3 2025), and $105.5 million (Q2 2025).